| 李 瑶,罗欢欢,田惠玲,胡 静,段林瑞,王四旺,谢艳华.强力定眩片及联合他汀类对高脂血症小鼠的降脂作用[J].,2023,(1):29-34 |
| 强力定眩片及联合他汀类对高脂血症小鼠的降脂作用 |
| Effects of Qianglidingxuan Tablet and its Combination with Statins on Hyperlipidemia Mice |
| 投稿时间：2022-04-29 修订日期：2022-05-26 |
| DOI：10.13241/j.cnki.pmb.2023.01.006 |
| 中文关键词: 强力定眩片 瑞舒伐他汀钙片 高脂血 联合用药 |
| 英文关键词: Qianglidingxuan table Rosuvastatin calcium tablet Hyperlipidemia Combination of drugs |
| 基金项目:陕西省生物医药重点实验室项目（2018SZS-41）；陕西省重点研发计划项目（2021ZDLSF03-07）；陕西省科技厅技术创新引导专项（2021YFBT-109-02） |
|
| 摘要点击次数: 500 |
| 全文下载次数: 506 |
| 中文摘要: |
| 摘要 目的：探讨强力定眩片及联合他汀类药物的降脂作用，通过对上市药品再评价，指导临床合理用药。方法：采用60% kcal高脂饲料建立高脂血症小鼠模型，同时灌胃给予强力定眩片或瑞舒伐他汀钙片8周，于给药2、4、8周分别检测血清中血脂水平，8周给药结束后检测血清及肝脏中总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL-C）和低密度脂蛋白（LDL-C）含量，H&E染色和油红O染色观察肝脏脂肪病变情况。结果：给药2周、4周和8周，瑞舒伐他汀钙片组、强力定眩片高、中剂量组以及联合给药组TC、TG和LDL-C水平均低于模型组，差异具有统计学意义（P<0.05或P<0.01），HDL-C高于模型组（P<0.05），随着给药时间延长，药物的降脂作用更明显。H&E和油红O染色结果显示，模型组小鼠肝脏脂肪病变严重，出现脂肪空泡和红色脂滴，强力定眩片能成剂量依赖性改善肝脏脂肪病变，联合用药后肝脏脂肪病变改善最为显著，肝脏细胞基本恢复正常，肝脏细胞排列整齐，仅存在少量红色脂滴和脂肪空泡。结论：在观察的时间段（2周～8周），随着用药时间的延长，除强力定眩片低剂量组外，各组对血脂指标改善明显，肝脏脂肪病变程度减轻，脂滴减少，强力定眩片呈现剂量依赖性，联合用药后强力定眩片和瑞舒伐他汀钙片具有协同降脂作用。本研究为临床合理用药提供了实验依据。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of Qiangli Dingxuan Tablets（QLDX）combined with rosuvastatin calcium on the treatment of hyperlipidemia mice, which may give some guides to doctors working for the rational use of post-marketing drugs. Methods: Hyperlipidemia mice models were established successfully by feeding with 60% KCAL high-fat diet. Mice were administered QLDX or rosuvastatin calcium tablets by gavage for 8 weeks. Blood lipid levels were detected at 2, 4, and 8 weeks after administration. The contents of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) in serum and liver were detected after 8 weeks of administration. HE staining and oil red O staining were used to observe hepatic adipose lesions. Results: After 2, 4 and 8 weeks of administration, the contents of TC, TG and LDL-C in rosuvastatin calcium tablet group, high-dose, medium-dose and combined administration groups were lower than those in the model group, and the differences were statistically significant (P<0.05 or P<0.01), HDL-C was higher than that of model group (P<0.05), the hypolipidemic effect was more obvious with the prolongation of administration time. HE and oil-red O staining results showed that the hepatic adipose lesions in model group were serious with fat vacuoles and red fat droplets. QLDX can improve hepatic adipose lesions in a dose-dependent manner, and the improvement was most significant after combined administration. The liver cells basically returned to normal, and the liver cells were arranged neatly, with only a few red lipid droplets and fat vacuoles. Conclusion: During the observation period (2 weeks to 8 weeks), with the extension of the medication time, except for the QLDX low-dose group, the indexes of blood lipid of each group were significantly improved, the degree of hepatic adipose lesions was reduced, the lipid droplets were reduced and the effects are dose-dependent. The results showed that the combination of QLDX and rosuvastatin calcium tablets had synergistic hypolipidemic effect. This study provides an experimental evidence for the rational use of QLDX and rosuvastatin calcium tablets in clinical practice. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
